Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

279 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460

Dyslipidemia Healthy Volunteers

COMPLETED PHASE1

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

NCT01879020

Dyslipidemia

COMPLETED PHASE1

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598

Mild Dyslipidemia

COMPLETED PHASE1

A Drug Interaction Study Between Simvastatin and GSK376501

NCT00605449

Type 2 Diabetes Mellitus

COMPLETED PHASE1

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

NCT01970215

Dyslipidemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAP311 capsules

Patients will receive TAP311 capsule orally once daily for 14 days.

Group Type EXPERIMENTAL

TAP311 capsules

Intervention Type DRUG

Placebo of TAP311 capsules

Matching placebo to TAP311 capsule, once daily for 14 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAP311 capsules

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients 18 to 80 years (inclusive) of age.
* Patients are not treated for dyslipidemia with medications other than HMG-CoA reductase inhibitors (statins) for at least 4 weeks prior to Day 1. Patients should be on stable doses of current medications, if any, for at least 3 months to be eligible.
* Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 40 kg/m2.

Exclusion Criteria

* Use of other investigational drugs at the time of enrollment
* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
* Use of lipid modifying agents (e.g. fenofibrate, niacin, omega-3 fatty acids, etc.) other than statins will exclude subjects.
* Pregnant or nursing (lactating) women
* Diabetic patients whose plasma glucose is not well controlled by stable diabetic treatment for at least 3 months
* Heavy smokers (smoke more than 10 cigarettes a day routinely and who cannot refrain from smoking during the study).
* Women of child-bearing potential (WOCBP) can be included but must use highly effective contraception
* Significant illness within two (2) weeks prior to initial dosing
* History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No